



Expression of colorectal neoplasia differentially expressed in anaplastic thyroid carcinoma and its effect on cancer cell proliferation

Lili Du¹, Qingsong Zhao², Jingjing Li¹, Mingli Wang¹, Hong Qiao¹

¹Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, Harbin, China; ²Department of Endocrinology and Metabolism, The Fourth Affiliated Hospital of Harbin Medical University, Harbin, China

Contributions: (I) Conception and design: L Du, H Qiao; (II) Administrative support: L Du, H Qiao; (III) Provision of study materials or patients: L Du, Q Zhao, J Li; (IV) Collection and assembly of data: L Du, M Wang; (V) Data analysis and interpretation: L Du, Q Zhao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Hong Qiao. Department of Endocrinology and Metabolism, The Second Affiliated Hospital of Harbin Medical University, No. 246 Xuefu Road, Nangang District, Harbin 150001, China. Email: qiaohong@hrbmu.edu.cn.

Background: The incidence of anaplastic thyroid cancer (ATC) is high among human cancers. Colorectal neoplasia differentially expressed (CRNDE) is highly expressed in common tumors, and is therefore a potential molecular target for anti-tumor therapy. However, the function of CRNDE in ATC remains elusive.

Methods: The Gene Expression Omnibus (GEO) database was used to screen the differential expression of long-noncoding RNA (lncRNA) in ATC tissues. The Cancer Genome Atlas (TCGA) database was used to analyze the expression of CRNDE in thyroid cancer (THCA) tissues and its impact on patient prognosis. Quantitative real-time PCR (qRT-PCR) was used to determine the expression level of CRNDE in tumor and control tissues. The biological function of CRNDE in THCA was explored using TCGA RNA sequencing (RNA-seq) data analysis. ATC cell lines with low and high CRNDE expression were selected for CRNDE siRNA transfection, and the proliferation of cells was detected in each group.

Results: The GEO and TCGA databases analysis results showed that CRNDE was highly expressed in ATC tissues, which is related to the poor prognosis of THCA patients. Also, the expression of CRNDE in the ATC cell line, ARO (human thyroid cancer cell line), was relatively high, while the expression in sw579 is relatively low. Therefore, ARO and sw579 were chosen for CRNDE small interfering RNA (siRNA) transfection. Compared with negative control (si-NC), the expression of CRNDE in si-CRNDE-1, si-CRNDE-2, and si-CRNDE-3 was reduced, indicating that the inhibitory effect was significantly enhanced and the cell proliferation ability was reduced, and the cell cycle is arrested in the G0/G1 phase. Finally, it was found that the wnt3a, β -catenin, and cyclinD1 protein expressions of si-CRNDE-1 and si-CRNDE-2 were significantly reduced.

Conclusions: The high expression of CRNDE in ATC tissues may promote the proliferation of ATC cells by regulating the Wnt/ β -catenin signaling pathway. CRNDE may be a potential molecular target for the treatment of ATC.

Keywords: Anaplastic thyroid cancer (ATC); colorectal differential expression of lncRNA; cell cycle; cell proliferation; Wnt/ β -catenin

Submitted Jan 25, 2022. Accepted for publication Apr 08, 2022.

doi: 10.21037/atm-22-945

View this article at: <https://dx.doi.org/10.21037/atm-22-945>

Introduction

The incidence of anaplastic thyroid cancer (ATC) is high among human cancers, and also exhibits high invasiveness, metastasis, and uncontrolled tumor spread at the time of diagnosis (1). Due to the resistance of ATC to traditional thyroid cancer (THCA) treatment [including inhibition of thyroid stimulating hormone (TSH) and radioactive iodine], it has a poor prognosis, including a median survival of only 5 months and a 1-year survival rate of less than 20% (2). At present, there are not effective treatments for this problematic tumor. Exploration of the pathogenesis of ATC may provide new insights into developing an effective treatment.

Long-noncoding RNAs (lncRNAs) are endogenous RNA molecules with more than 200 nucleotides, which do not exert a protein encoding function, and play a critical role in multiple normal biological processes, such as cell development, differentiation, and motility (3). A previous study has shown that abnormal expression of lncRNAs may promote tumor development, acting as tumor suppressor genes and oncogenes to regulate tumor cell proliferation, invasion, metastasis, and other malignant progression. Targeted regulation of lncRNAs can significantly inhibit the malignant progression of tumors (4).

Through bioinformatics analysis of The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) data, we found that colorectal neoplasia differentially expressed (CRNDE) plays an important role in ATC progression (5-7). CRNDE is located on human chromosome 16, and can be used as a biomolecular marker (8). CRNDE is highly expressed in common tumors such as colorectal, liver, and lung cancers. It also promotes the proliferation, migration, invasion, and angiogenesis of tumor cells, and inhibits apoptosis, which is a potential molecular target for anti-tumor therapy (8-10). However, the expression of CRNDE in ATC and its mechanism of action remain unknown. In this study, TCGA was used to analyze the expression of CRNDE in ATC tissues as well as its relationship to

patient prognosis, and explored whether CRNDE plays a role as a cancer-promoting factor in ATC, with the aim of obtaining an important basis of CRNDE as a potential molecular target for the treatment of ATC. We present the following article in accordance with the MDAR reporting checklist (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-945/rc>).

Methods

Transcriptome data acquisition and pre-processing

We obtained ATC gene expression profiling datasets (11,12), GSE65144 GSE33630, GSE29265 (no citation), and GSE53157, from the GEO (<https://www.ncbi.nlm.nih.gov/geo/>) database. The basic information of these four datasets is shown in *Table 1*. The THCA transcriptome data and corresponding clinical characteristics of patients were downloaded from the publicly available TCGA (<http://cancergenome.nih.gov/>) database (*Table S1*). A total of 510 THCA tissue samples and 58 adjacent normal tissues were extracted from TCGA. Patients in TCGA cohort who failed to meet the following criteria were eliminated: (I) THCA transcriptome data with basic survival information including, overall survival status and survival time; and (II) primary tumor samples (as opposed to metastatic tumor samples). Finally, 502 THCA samples and 58 adjacent normal tissues samples from TCGA were included. The clinical characteristics of THCA patients in the TCGA database are summarized in *Table 2*. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Experimental reagents and instruments

Human thyroid cancer cell line ARO, FRO, sw579 and 8505c were obtained from the Cell Bank of Shanghai Academy of Sciences (Shanghai, China). The culture medium, pancreatin, and fetal bovine serum (FBS) were

Table 1 ATC dataset in GEO database

GEO_ID	Samples	Case/control	Country	Platforms	Chip
GSE65144	34	16/18	USA	GPL570	HG-U133_Plus_2
GSE33630	105	11/45	Belgium	GPL570	HG-U133_Plus_2
GSE29265	49	9/20	Belgium	GPL570	HG-U133_Plus_2

ATC, anaplastic thyroid cancer; GEO, Gene Expression Omnibus.

Table 2 Univariate Cox regression analysis of the effects of 11 lncRNAs on the prognosis of THCA patients

Gene name	Ensembl.id	Chromosomal position	P	HR
<i>LINC01116</i>	ENSG00000163364	chr2: 176629572-176637931 (-)	9.28E-01	0.96
<i>LINC00265</i>	ENSG00000188185	chr7: 39733430-39793092 (+)	7.72E-01	0.86
<i>APTR</i>	ENSG00000214293	chr7: 77657659-77696267 (-)	8.37E-01	1.11
<i>LINC00271</i>	ENSG00000231028	chr6: 135497422-135813990 (+)	2.55E-01	0.56
<i>LINC00865</i>	ENSG00000232229	chr10: 89829483-89840861 (+)	9.50E-01	0.97
<i>LINC00886</i>	ENSG00000240875	chr3: 156747343-156817062 (-)	1.97E-01	1.95
<i>CRNDE</i>	ENSG00000245694	chr16: 54845189-54929189 (-)	2.99E-02	3.51
<i>LINC01094</i>	ENSG00000251442	chr4: 78638780-78683185 (+)	6.72E-01	1.24
<i>RMST</i>	ENSG00000255794	chr12: 97430884-97598415 (+)	1.52E-01	0.46
<i>LINC01003</i>	ENSG00000261455	chr7: 152463786-152465549 (+)	8.77E-01	1.08
<i>CHASERR</i>	ENSG00000272888	chr15: 92819540-92899701 (+)	1.77E-01	0.50

+, positive strand; -, negative strand. LncRNA, long-noncoding RNA; THCA, thyroid cancer; HR, hazard rate.

purchased from Gibco (United States). The TRIzol reagent and RNA extraction kit were purchased from TaKaRa (Japan). CRNDE and internal reference glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers were obtained from Jierui Bioengineering Co., Ltd. (Shanghai, China). The AMV (Avian Myeloblastosis Virus) One-step Reverse Transcription PCR (RT-PCR) kit was obtained from Shengong Bioengineering Co., Ltd. (Shanghai, China). The CRNDE small interfering RNA (siRNA) was purchased from Ruibo Biological Co., Ltd. (Guangzhou, China). The Lip 2000 and Invitrogen reagents were obtained from Invitrogen (United States). The 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide MTT proliferation detection reagents were obtained from Airan Biotechnology Co., Ltd. (Beijing, China). The Giemsa staining solution, cell cycle detection kit, and bicinchoninic acid (BCA) protein concentration detection kit were purchased from Shanghai Biyuntian Biological Co., Ltd. Protein lysate was purchased from Solarbio (Beijing, China). The polyvinylidene difluoride (PVDF) membrane was purchased from Promega (United States). The efficient chemiluminescence (ECL) protein exposure kit was purchased from Huiying Biotechnology Co., Ltd. (Shanghai, China). Antibodies were purchased from Abcam (United Kingdom).

Cell culture

ARO, FRO, sw579, and 8505c of the ATC cell lines were

removed from liquid nitrogen and quickly recovered in a 37 °C water bath. After centrifugation at 800 rpm for 5 minutes, the freezing solution was discarded, and the cells were resuspended in a medium containing 10% FBS and placed in a fully humidified incubator with 5% carbon dioxide (CO₂) at 37 °C. When a color change was observed in the cells, the medium was immediately replaced with fresh medium. The overgrown cells were washed with phosphate buffer saline (PBS) once, and trypsin was used for digestion according to the ratio of 1:2 for cells (13).

RNA extraction and qRT-PCR

Total RNA was extracted from the cell lines using TRIzol (Invitrogen, Carlsbad, CA, USA) as directed by the manufacturer's instructions. The reverse transcription reaction was performed with the Moloney Leukemia Virus Reverse Transcriptase Kit using 1µg of total RNA as a template to create a high-quality cDNA. To evaluate the expression of lncRNA, the cDNA samples were amplified by qRT-PCR using the Green Mix SYBR (Promega), and GAPDH was employed as the internal control to standardize their expression. CRNDE, (forward, 5'-TGTC AAGGGTTTGA ACTGCTAAT-3'; reverse, 5'-GATAAGCATGCTACAAGCTCTGACA-3') (14).

CRNDE siRNA transfection

The expression level of CRNDE in ATC cells was detected

by qRT-PCR, and ATC cells with the highest and lowest CRNDE expression were selected for siRNA transfection. Cells in the logarithmic growth phase were collected by trypsinization after washing once with PBS. After counting the cells, they were inoculated into six-well plates at 2×10^5 cells/well, and divided into negative control (si-NC), si-CRNDE-1, si-CRNDE-2, and si-CRNDE-3 groups and placed in an incubator for culturing. After culturing for 12 h, Lip 2000 was mixed with siRNA in each group according to the manufacturer's instructions, and transfected into each group of cells. After culturing for 8 h, the medium was replaced with fresh medium, and culturing was continued for 48 h. The expression of CRNDE in each group was detected by qRT-PCR to verify the effect of CRNDE siRNA transfection, and two siRNA sequences with obvious inhibitory effects were selected for a subsequent study (15).

MTT for cell proliferation ability

The ATC cells were collected by trypsin digestion, and 1,500 cells per well were seeded in a 96-well plate. Each group was set with six parallel multiple wells and placed in an incubator for culturing. After culturing for 12 h, transfection of siRNA was carried out according to the above transfection method. The 20 μ L MTT reagent was added to each well at 0, 24, 48, and 72 h, respectively. After culturing in an incubator for 4 h, the culture medium was discarded, and 150 μ L dimethyl sulfoxide (DMSO) was added for shock mixing. After the crystals are completely dissolved, a microplate reader (United States) was used to detect the cell optical density (OD) at 490 nm. All experiments were performed in triplicate (16).

Flow cytometry for cell cycle

ATC cells transfected for 48 h were collected by trypsinization, washed with PBS three times, and fixed with pre-cooled absolute ethanol (three in each group in parallel). After washing once with PBS, cell cycle staining buffer, propidium iodide (PI) staining solution, and RNase were added, mixed well, and incubated at 37 °C for 15 min. Flow cytometry was used to detect the cell cycle ratio.

Scratch test for cell migration ability

The transfected ATC cells of each group were collected by trypsinization and seeded into a six-well plate at 4×10^5 cells/well, with three parallel multiple wells in each group, and placed

in an incubator for culturing. After culturing for 12 h, a scratcher was used to make a scratch in a six-well plate. After using PBS to wash off the exfoliated cells, serum-free medium was added, and the width of the cell scratch was recorded by taking pictures, which was recorded as 0 h. After culturing in an incubator for 48 h and washing off the exfoliated cells with PBS, a photo was taken to record the width of the cell scratch, which was recorded as 48 h. The cell migration ability was expressed by cell migration rate (17).

$$\text{Cell migration rate} = \frac{(1 - 48\text{h cell scratch width})}{0\text{h cell scratch width}} \times 100\% \quad [1]$$

Western blotting

The ATC cells in each group, which were transfected for 48 h, were collected by trypsinization, washed with PBS three times, and lysed with protein lysate. After ultrasonic lysis for 20 min, high-speed centrifugation was performed at 4 °C for 30 min. The supernatant was then collected and the protein concentration was detected using the BCA detection kit. Then, the loading buffer was added and boiled for 3 min, and the denatured protein was separated by gel electrophoresis. The protein was transferred to the PVDF membrane via wet transfer, and the PVDF membrane was sealed with skimmed milk. After washing once with TBST, the PVDF membrane was incubated with the target primary antibody at 4 °C overnight and the secondary antibody at room temperature for 1 h. After washing with TBST three times, the ECL kit was used to expose the protein bands (17).

Econazole regulates CRNDE to inhibit ATC cell proliferation

ATC cells were collected by trypsin digestion, and 1,500 cells per well were seeded in a 96-well plate, divided into NC, econazole, overexpression (oe)-CRNDE, and econazole + oe-CRNDE groups (with six parallel multiple wells in each group), and placed in the incubator for cultivation. After culturing for 12 h, the NC group was transfected with unrelated sequence therapy. The econazole group was transfected with the concentration of half maximal inhibitory concentration (IC₅₀) econazole, the oe-CRNDE group was transfected with CRNDE overexpression plasmid, and the econazole + oe-CRNDE group was transfected with IC₅₀ econazole at the same time. After incubation for 48 h, 20 μ L of MTT reagent was added to each well. After culturing in an incubator for 4 h, the culture medium was

discarded, and a further 150 μL of DMSO was added for shock mixing. When the crystals were completely dissolved, the absorbance (OD) at 490 nm was detected by a microplate reader. All experiments were performed in triplicate (17).

The Connectivity Map

The Connectivity Map (CMap, <https://clue.io/>) has collected 1,309 compounds and contains more than 7,000 gene expression profiles, and reveals the connection between diseases, genes, and drugs. It is used to discover potential treatments for diseases drug. The Score value in CMap was between -1 and 1 ; a positive value indicated that the drug has a disease-promoting effect, while a negative value suggested that the drug has an inhibitory effect on the disease. A larger absolute value signified a stronger correlation.

Statistical analysis

SPSS17.0 statistical software (<https://www.ibm.com/products/spss-statistics>) was used for analysis. All P value calculations were performed using an unpaired *t*-test or non-parametric one-way analysis of variance (ANOVA) and other special analyses. $P < 0.05$ was considered to be indicative of statistical significance.

Results

Screening of different expression of LncRNA in ATC

For ATC data, we obtained the GSE65144, GSE33630, and GSE29265 datasets from the GEO database (Table 1). According to the threshold of $|\text{Log}_2(\text{FC})| > 1$, $P < 0.0001$, a total of 33 significant probes in the GSE65144 were determined, involving 30 lncRNAs with different expressions (Figure 1A). Also, the GSE33630 involved 74 differentially-expressed lncRNAs, and the GSE29265 involved 47 differentially expressed lncRNAs. The Venn diagram results showed that a total of 11 lncRNAs were differentially expressed in THCA and control tissues (Figure 1B,1C).

Using TCGA data, a univariate analysis of 11 genes was performed (as shown in Table 2), which showed that CRNDE expression was the most significant, and thus, a survival curve was drawn for it (Figure 1D). At the same time, multivariate Cox regression analysis showed that high CRNDE expression was an important factor for the poor prognosis of THCA patients, as shown in Table 3. Figure 2A showed that compared with 58 normal thyroid tissues in TCGA dataset,

CRNDE was highly expressed in 502 THCA tissues,

To assess the efficacy of CRNDE in diagnosing THCA, we performed five-fold cross-validation using a logistic regression model in TCGA database. The 502 tumor samples and 58 normal samples were separately randomly selected to form training and validation sets (7:3), which avoided the size imbalance of the two groups. The area under the receiver operating characteristic (ROC) curve (AUC) was used to evaluate the sensitivity (true positive rate) and specificity (true negative rate) of CRNDE for the diagnosis of THCA in TCGA database using the ROCR package (<https://cran.r-project.org/web/packages/ROCR/index.html>). As a result, the AUC values were > 0.75 in each fold (Figure 2B). The average values of accuracy, precision, recall, and F1-score were 0.89, 0.89, 1.00, and 0.94, respectively (Table 4). In summary, CRNDE showed the greatest influence, and the hazard rate (HR) of CRNDE was the largest (Table 2), so this gene was selected for further study.

Moreover, the expression level of CRNDE was analyzed in ATC's GEO-meta database. The results of both datasets (GSE33630 and GSE29265) showed that CRNDE was specifically and highly expressed in ATC tissues (Figure 2C). These results indicated that CRNDE may play an important role in ATC. Therefore, CRNDE was selected for follow-up research.

CRNDE promotes the proliferation and migration of ATC cells

In order to verify the above results, qRT-PCR was performed, which showed that CRNDE expression was relatively high in ARO, and was relatively low in sw579 (Figure 3A). To explore the molecular mechanism of CRNDE and its effect on tumor proliferation, we selected for CRNDE siRNA transfection for subsequent experimental studies. Following transfection of CRNDE siRNA with ARO and sw579 cells for 48 h, we found that the relative expression of CRNDE in the si-CRNDE-1, si-CRNDE-2, and si-CRNDE-3 groups of ARO and sw579 cells were significantly decreased compared with the si-NC group ($P < 0.05$). Also, the inhibitory effect of CRNDE in the ARO and sw579 cells si-CRNDE-1 and si-CRNDE-2 groups was more significant. Thus, both were selected for subsequent functional experiments (Figure 3B).

MTT was used to determine the effect of CRNDE siRNA on the proliferation ability of ATC cells. The results showed that compared with the si-NC group, the




Figure 1 GEO database analysis of differentially-expressed lncRNAs in THCA tissues. (A) There were 30 differentially-expressed lncRNAs in the GSE65144 database, and CRNDE was one of them. (B) Differentially-expressed lncRNAs in the three datasets of (GSE65144, GSE33630, and GSE29265). The red square indicates a total of 11 lncRNAs were differentially expressed in THCA and control tissues. (C) Eleven lncRNAs were differentially expressed in THCA and control tissues. (D) KM curve of the CRNDE expression level. GEO, Gene Expression Omnibus; lncRNA, long-noncoding RNA; THCA, thyroid cancer; CRNDE, colorectal neoplasia differentially expressed; KM, Kaplan-Meier.

proliferation ability of ARO and sw579 cells in the si-CRNDE-1 and si-CRNDE-3 groups were markedly reduced ($P < 0.05$, Figure 3C). Flow cytometry was used to detect the effect of CRNDE siRNA on the ATC cell cycle. The results showed that compared with the si-NC group, the ratio of G0/G1 cells in the si-CRNDE-1 and siCRNDE-2 groups of ARO and sw579 cells was also significantly increased ($P < 0.05$, Figure 3D). The scratch test was used to evaluate the effect of CRNDE siRNA on the migration ability of ATC cells. The results showed that the migration ability of ARO and

sw579 cells in the si-CRNDE-1 and the si-CRNDE-3 groups was notably reduced compared with the si-NC group ($P < 0.05$, Figure 3E).

CRNDE promoted ATC proliferation via the Wnt/ β -catenin signaling pathway

To explore the molecular mechanism of CRNDE, RNA-seq data analysis of 502 THCA tissues in the TCGA was conducted to identify the possible biological functions of

Table 3 Univariate and multivariate Cox regression analysis of the effects of CRNDE and clinical factors on the prognosis of THCA patients

Variables	Univariate analysis			Multivariate analysis		
	HR	95% CI	P value	HR	95% CI	P value
CRNDE expression	2.12	1.33–3.40	1.70E-03	2.08	1.17–3.72	1.31E-02
Tumor stage (stage III_IV vs. I_II)	7.14	2.3–22.19	6.82E-04	0.52	0.09–3.03	4.68E-01
T stage (T3_T4 vs. T1_T2)	3.11	1.08–8.96	3.56E-02	0.54	0.10–2.86	4.71E-01
N stage (N1 vs. N0)	1.47	0.48–4.51	4.97E-01	–	–	–
M stage (M1 vs. M0)	4.74	1.01–22.22	4.84E-02	–	–	–
Residual tumor (R1_R2 vs. R0)	3.69	1.11–12.25	3.32E-02	11.55	2.14–62.44	4.50E-03
Gender (male vs. female)	1.93	0.7–5.34	2.05E-01	–	–	–
Race (white vs. others)	1.41	0.32–6.22	6.48E-01	–	–	–
Age	1.16	1.10–1.22	2.08E-08	1.19	1.10–1.28	3.52E-06
Disease history (yes vs. no)	0.16	0.02–1.23	7.89E-02	–	–	–
Location (isthmus vs. bilateral)	1.11	0.1–12.47	9.31E-01	–	–	–
Location (left lobe vs. bilateral)	0.95	0.19–4.81	9.52E-01	–	–	–
Location (right lobe vs. bilateral)	0.90	0.18–4.53	9.02E-01	–	–	–

CRNDE, colorectal neoplasia differentially expressed; THCA, thyroid cancer; HR, hazard rate; CI, confidence interval.

CRNDE in THCA. The Gene Ontology (GO) enrichment analysis of 230 related genes ($|R| > 0.4$) showed that CRNDE affected cell growth and proliferation ($P < 0.005$, *Table 5*), and that the signaling pathways enriched by the high-expressing CRNDE group include the WNT (wnt signaling pathway), transforming growth factor-beta signaling pathway (TGF-beta), and cancer-related pathways (*Figure 4A, 4B*).

Cross 150 signal genes from the KEGG database (c2.cp.kegg.v7.4.symbols.gmt) and positively related genes were intersected to obtain 47 genes, as shown in *Figure 4C* and *Table S2*. After CRNDE siRNA transfected ARO and sw579 cells for 48 h, compared with the si-NC group, the relative expressions of Wnt3a, β -catenin and CyclinD1 protein in the si-CRNDE-1 group and si-CRNDE-2 group of ARO and sw579 cells were significantly reduced ($P < 0.05$, *Figure 4D*).

Screening of small molecule drugs with potential efficacy using the Connectivity Map (CMap)

The differentially expressed genes (differential genes between CRNDE expression groups, $P < 0.05$, $|\log_2FC| > 0.5$) were uploaded to the CMap database, which screened out the small molecule compounds that were negatively

correlated with the correlation coefficient (*Table 6*). Previous studies have shown that econazole and terazosin exert anti-tumor effects (18,19). The IC₅₀ value of econazole on ARO and sw579 cells was the lowest detected by MTT ($P < 0.05$, *Figure 5A*). Lastly, the MTT test showed that econazole inhibited the proliferation of ARO and sw579 cells in a dose-dependent manner ($P < 0.05$, *Figure 5B*).

Econazole regulated the expression of CRNDE and inhibited the proliferation of ATC cells

In order to explore the targeting effect of drugs on CRNDE, we used MTT to determine the effect of econazole on the reversal the effect of CRNDE in ATC cell proliferation. The results showed that compared with the NC group, the proliferation of ARO and sw579 cells in the econazole group and econazole + oe-CRNDE group were reduced, and the proliferation ability of ARO and sw579 cells in the oe-CRNDE group was increased. Compared with the econazole group, the proliferation ability of ARO and sw579 cells in the econazole + oe-CRNDE group was increased (*Figure 5C*). Therefore, we believe that econazole exerts an anti-tumor effect by reversing CRNDE.

Western blotting was used to detect the effect of econazole on regulating the expression of CRNDE and




Figure 2 TCGA database analysis of the significance of CRNDE expression in ATC tissues. (A) The TCGA database showed that CRNDE was highly expressed in THCA tissue compared to normal thyroid tissue. (B) Logistic regression analysis showed that CRNDE played a critical role in the diagnosis of THCA. (C) Both GSE33630 and GSE29265 datasets showed that CRNDE was specifically and highly expressed in ATC tissues. CRNDE, colorectal neoplasia differentially expressed; TCGA, The Cancer Genome Atlas; PTC, papillary thyroid carcinoma; ATC, anaplastic thyroid cancer; THCA, thyroid cancer.

Table 4 CRNDE evaluation indicators in five-fold cross-validation

Group	Accuracy	Precision	Recall	F1-score	AUC
Sub-folder 1	0.89	0.89	0.99	0.94	0.78
Sub-folder 2	0.89	0.89	1.00	0.94	0.88
Sub-folder 3	0.89	0.89	0.99	0.94	0.86
Sub-folder 4	0.89	0.89	0.99	0.94	0.79
Sub-folder 5	0.89	0.89	1.00	0.94	0.81
Average	0.89	0.89	1.00	0.94	0.83

CRNDE, colorectal neoplasia differentially expressed; AUC, area under the receiver operating characteristic curve.




Figure 3 CRNDE was highly expressed in ATC cell line and promoted ATC proliferation (n=3). (A) The expression level of CRNDE in ATC cell line by qRT-PCR. (B) The effect of CRNDE siRNA transfection into ATC cell line by qRT-PCR. (C) The effect of interfering CRNDE on ATC cell proliferation by MTT test. (D) The influence of interference CRNDE on ATC cell cycle was detected. (E) The influence of interference CRNDE on ATC cell migration ability, based on scratch test. The cell migration was observed under the optical microscope. *, $P < 0.05$. CRNDE, colorectal neoplasia differentially expressed; ARO and FRO, human thyroid cancer cell lines; si-NC, negative control; OD, optical density; ATC, anaplastic thyroid cancer; qRT-PCR, quantitative real-time PCR; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide.

Table 5 TCGA database analysis of biological functions of CRNDE in tumors

Gene set	Size	Overlap	Expect	Enrichment ratio	P value	Description
GO:0040008	670	12	5.869434777	2.044489879	0.014836175	Regulation of growth
GO:0061061	610	11	5.343813753	2.058454974	0.018479803	Muscle structure development
GO:0040007	961	15	8.418696748	1.781748464	0.021382547	Growth
GO:1901137	712	12	6.237369495	1.923887948	0.022694452	Carbohydrate derivative biosynthetic process
GO:0008285	667	11	5.843153726	1.882545029	0.032733124	Negative regulation of cell proliferation
GO:0007423	531	9	4.65174607	1.934757372	0.044170929	Sensory organ development
GO:0048589	623	10	5.457698308	1.832274236	0.047470184	Developmental growth

TCGA, The Cancer Genome Atlas; CRNDE, colorectal neoplasia differentially expressed.

inhibiting the proliferation of ATC cells. The results showed that compared with the NC group, the expression of wnt3a, β -catenin, and cyclinD1 in ARO and sw579 cells in the econazole and the econazole + oe-CRNDE groups were significantly reduced. Importantly, the expression of wnt3a, β -catenin, and cyclinD1 proteins increased in ARO and sw579 cells in the CRNDE group. Lastly, compared with the econazole group, the expression of wnt3a, β -catenin, and cyclinD1 proteins in the econazole + oe-CRNDE group were markedly increased (*Figure 5D*).

Discussion

THCA is the most common endocrine cancer, and approximately 67,400 cases of THCA were diagnosed in the United States in 2019 (11). THCA is divided into papillary thyroid carcinoma (PTC) and follicular thyroid cancer (FTC), poorly differentiated (PDC), and undifferentiated THCA (ATC) according to the histological characteristics. The transmissibility of THCA increases with age, and ATC is the most transmissible thyroid cancer. Although it accounts for only 2% of all THCA, ATC has a high mortality rate and was the main cause of THCA death (2). Moreover, epidemiological surveys showed that the incidence of ATC increased from 1973 to 2014 (12). Therefore, it is clinically significant to explore effective treatment methods to improve the prognosis of ATC patients. ATC treatments include chemotherapy, radiotherapy, immunotherapy, etc.; however, the existing treatments cannot improve the survival of ATC patients (2). As a new treatment, targeted molecular therapy has become a potent method to reduce the mortality of malignant tumor patients (20). Therefore, exploring the pathogenesis of ATC and finding new molecular therapeutic targets may reveal

new strategies for ATC therapy.

The molecular mechanisms of tumor pathogenesis are complex. Oncogene activation, tumor suppressor gene inactivation, and epigenetic changes play key roles in the development of tumors. However, the underlying epigenomic and transcriptome changes that lead to ATC have been relatively poorly studied (21). Epigenetic modification refers to the regulation of gene function through histone modification, DNA methylation, chromatin structure remodeling, and non-coding RNA regulation, which affects tumor progression (22). With the rapid development of second-generation sequencing technology, increasingly abnormally expression of lncRNAs has gradually been discovered in tumors, including ATC (5). The GEO and TCGA contain public databases, such as differentially-expressed genes, MicroRNA (miRNA), and lncRNA in tumor diseases, which are important bioinformatics analysis data for obtaining tumor-related molecules (23).

The GEO database contains four ATC datasets. The sample size of the GSE53157 dataset was relatively small and was eliminated. There are 11 differentially expressed lncRNAs in the other three THCA datasets. By analyzing the effects of differentially-expressed lncRNAs in ATC on the prognosis of patients, the results showed that among 11 lncRNAs, only CRNDE was highly expressed in THCA, leading to a decline in patient survival. This suggests that CRNDE may play a key role in promoting THCA. Further analysis of the expression level of CRNDE in the GEO database showed the specific high expression of CRNDE. Also, the expression level of CRNDE in normal tissue (NT), papillary thyroid carcinoma (PTC), and ATC tissues increased in turn, suggesting that CRNDE may exert important biological functions in ATC.

CRNDE is a lncRNA that is closely related to tumors,




Figure 4 CRNDE promoted ATC proliferation via the Wnt/ β -catenin signaling pathway. (A) The dot plot of gene enrichment analysis results; (B) The canonical plot of gene set enrichment analysis results; (C) correlation between CRNDE and Wnt/ β -catenin-related molecules in THCA samples from TCGA database; (D) the effect of CRNDE on the Wnt/ β -catenin signaling pathway was detected by western blotting. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. NES, Normalized Enrichment Score; ARO, human thyroid cancer cell line; si-NC, negative control; CRNDE, colorectal neoplasia differentially expressed; ATC, anaplastic thyroid cancer; THCA, thyroid cancer; TCGA, The Cancer Genome Atlas.

Table 6 CMap results of small molecule compounds

Drug name	Molecular formula	Mean connective score	n	Enrichment	P value	Specificity
STOCK1N-35696	C17H18N4O3	-0.791	2	-0.98	8.70E-04	0.01
Ambroxol	C13H18Br2N2O	-0.353	4	-0.82	1.89E-03	0.01
Econazole	C18H15Cl3N2O	-0.578	4	-0.72	1.22E-02	0.10
Etoposide	C29H32O13	-0.543	4	-0.72	1.30E-02	0.09
Antazoline	C17H19N3	-0.601	4	-0.71	1.34E-02	0.01
Terazosin	C19H25N5O4	-0.323	4	-0.70	1.82E-02	0.09
Benzbromarone	C17H12Br2O3	-0.499	3	-0.79	1.97E-02	0.04




Figure 5 Econazole reversed the effect of CRNDE on ATC cell proliferation (n=3). (A) The IC₅₀ value of econazole, colistin, and terazosin on ATC cells for 48 h by MTT. (B) Econazole inhibited the proliferation of ARO and sw579 cells in a dose-dependent manner by MTT; (C) Econazole regulated the expression of CRNDE and inhibited the proliferation of ATC cells by MTT assays. *, P<0.05; #, P<0.05; (D) Econazole regulated the expression of CRNDE and inhibited the Wnt/β-catenin signaling pathway in ATC cells by western blotting. ARO, human thyroid cancer cell line; OD, optical density; NC, negative control; CRNDE, colorectal neoplasia differentially expressed; ATC, anaplastic thyroid cancer; IC₅₀, half maximal inhibitory concentration; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide.

and was originally discovered in colorectal cancer. Under normal conditions, CRNDE is highly expressed in normal tissues such as skin, breast, and testis, but is lowly or not expressed in colorectal mucosa (8). Under pathological conditions, high expression of CRNDE leads to the progression of a variety of tumors, and promotes the proliferation, migration, and invasion of tumor cells, while inhibiting cell apoptosis (9,10).

We combined the reported results and used the RNA-seq data from the TCGA database to verify the possible biological functions of CRNDE in THCA. The results showed that inhibition of CRNDE reduced the proliferative ability of ATC cells. Uncontrolled cell growth leading to malignant proliferation is an important feature of tumors, and abnormal cell cycle regulation is closely related to cell malignant proliferation (24). After inhibiting the expression of CRNDE, the two ATC cell cycles were blocked in the G0/G1 phase, which is consistent with previous studies on CRNDE in non-small cell lung cancer, acute lymphoblastic leukemia, and tongue squamous cell carcinoma (10,13,25). Under normal circumstances, the cell cycle is strictly regulated by cyclins. CyclinD1 is a key protein that promotes cells from the G0/G1 phase to S phase (14). The western blotting results showed that after inhibiting CRNDE expression, the expression of the cyclinD1 protein in the two ATC cells was significantly reduced. Wnt/ β -catenin is one of the classic signaling pathways regulating tumor cell proliferation (15), and the cyclinD1 protein is its downstream target gene (26). The *wnt3a* gene leads to the accumulation of β -catenin and its ectopic localization to the nucleus. The combination of β -catenin and T-cell factor/lymphoid enhancer-binding factor (TCF/LEF) transcription factors drives the expression of downstream target genes such as cyclinD1 (26). The results showed that the expression of *wnt3a* and β -catenin protein in the two ATC cells was markedly reduced. This indicates that CRNDE may regulate cell cycle proteins by inhibiting the Wnt/ β -catenin signaling pathway, inducing cell cycle arrest, and subsequently inhibiting cell proliferation (27,28).

The CMap database has collected 1,309 compounds and contains more than 7,000 gene expression profiles, revealing the connection between diseases, genes, and drugs, which can be used to discover potential drugs for the treatment of diseases. The CMap database is used to discover new molecular targeted drugs for the treatment of THCA (16,17). Previous results have shown that there are nine small molecule drugs that can be used as targeted therapeutics for CRNDE in THCA (29-31), however the

anti-tumor effect in THCA remains unclear. Tests have shown that the IC50 value of econazole on THCA cells is lower than other compounds. Therefore, econazole may have good therapeutic potential. Econazole is an imidazole compound, and as an effective broad-spectrum antifungal agent, it has shown anti-inflammatory effects. In recent decades, the anti-tumor effect of econazole has gradually been discovered, including in leukemia and other blood system tumors (32) as well as gastric cancer (18), and inhibits tumor proliferation, invasion, drug resistance, and other malignant biological behaviors (33,34). The MTT results confirmed that econazole significantly inhibited the proliferation of ATC cells, indicating an anti-tumor effect in THCA. Lastly, restoring the expression of CRNDE markedly weakened the inhibitory effect of econazole on the proliferation of ATC cells, and the inhibitory effect of econazole on the expression of *wnt3a*, β -catenin, and cyclinD1 proteins in ATC cells. It is suggested that econazole exerted its anti-cancer effect by regulating CRNDE.

In conclusion, this study systematically assessed the specific expression of CRNDE in ATC tissues and its potential prognostic value in ATC. It was experimentally verified that CRNDE plays a key role in promoting the development of ATC, providing a potential prognostic gene for ATC. Meanwhile, econazole inhibited the expression of CRNDE, which may be a potential therapeutic strategy for the treatment of ATC.

Acknowledgments

Funding: This study was funded by the National Natural Science Foundation of China (No. 82073491) and the National Natural Science Foundation of China (No. 81872560).

Footnote

Reporting Checklist: The authors have completed the MDAR reporting checklist. Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-945/rc>

Data Sharing Statement: Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-945/dss>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-945/>)

coif). All authors report that this study was funded by the National Natural Science Foundation of China (No. 82073491) and the National Natural Science Foundation of China (No. 81872560). The authors have no other conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013).

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Molinaro E, Romei C, Biagini A, et al. Anaplastic thyroid carcinoma: from clinicopathology to genetics and advanced therapies. *Nat Rev Endocrinol* 2017;13:644-60.
- Zhang R, Zhang Y, Tan J, et al. Antitumor Effect of 131I-Labeled Anti-VEGFR2 Targeted Mesoporous Silica Nanoparticles in Anaplastic Thyroid Cancer. *Nanoscale Res Lett* 2019;14:96.
- Charles Richard JL, Eichhorn PJA. Platforms for Investigating LncRNA Functions. *SLAS Technol* 2018;23:493-506.
- Sanchez Calle A, Kawamura Y, Yamamoto Y, et al. Emerging roles of long non-coding RNA in cancer. *Cancer Sci* 2018;109:2093-100.
- Tan X, Wang P, Lou J, et al. Knockdown of lncRNA NEAT1 suppresses hypoxia-induced migration, invasion and glycolysis in anaplastic thyroid carcinoma cells through regulation of miR-206 and miR-599. *Cancer Cell Int* 2020;20:132.
- Gou L, Zou H, Li B. Long noncoding RNA MALAT1 knockdown inhibits progression of anaplastic thyroid carcinoma by regulating miR-200a-3p/FOXA1. *Cancer Biol Ther* 2019;20:1355-65.
- Wang Y, Hou Z, Li D. Long noncoding RNAUCA1 promotes anaplastic thyroid cancer cell proliferation via miR-135a-mediated c-myc activation. *Mol Med Rep* 2018;18:3068-76.
- Lu Y, Sha H, Sun X, et al. CRNDE: an oncogenic long non-coding RNA in cancers. *Cancer Cell Int* 2020;20:162.
- Li Z, Wu G, Li J, et al. lncRNA CRNDE promotes the proliferation and metastasis by acting as sponge miR-539-5p to regulate POU2F1 expression in HCC. *BMC Cancer* 2020;20:282.
- Jing H, Xia H, Qian M, et al. Long noncoding RNA CRNDE promotes non-small cell lung cancer progression via sponging microRNA-338-3p. *Biomed Pharmacother* 2019;110:825-33.
- Pan Z, Li L, Fang Q, et al. Integrated Bioinformatics Analysis of Master Regulators in Anaplastic Thyroid Carcinoma. *Biomed Res Int* 2019;2019:9734576.
- Wang S, Wu J, Guo C, et al. Identification and Validation of Novel Genes in Anaplastic Thyroid Carcinoma via Bioinformatics Analysis. *Cancer Manag Res* 2020;12:9787-99.
- Pérez-Benavente B, Nasresfahani AF, Farràs R. Ubiquitin-Regulated Cell Proliferation and Cancer. *Adv Exp Med Biol* 2020;1233:3-28.
- Ren L, Yang S, Cao Q, et al. CRNDE Contributes Cervical Cancer Progression by Regulating miR-4262/ZEB1 Axis. *Onco Targets Ther* 2021;14:355-66.
- Ren Y, He W, Chen W, et al. CRNDE promotes cell tongue squamous cell carcinoma cell growth and invasion through suppressing miR-384. *J Cell Biochem* 2019;120:155-63.
- Ding Q, Mo F, Cai X, et al. LncRNA CRNDE is activated by SP1 and promotes osteosarcoma proliferation, invasion, and epithelial-mesenchymal transition via Wnt/ β -catenin signaling pathway. *J Cell Biochem* 2020;121:3358-71.
- Huan J, Xing L, Lin Q, et al. Long noncoding RNA CRNDE activates Wnt/ β -catenin signaling pathway through acting as a molecular sponge of microRNA-136 in human breast cancer. *Am J Transl Res* 2017;9:1977-89.
- Choi EK, Park EJ, Phan TT, et al. Econazole Induces p53-Dependent Apoptosis and Decreases Metastasis Ability in Gastric Cancer Cells. *Biomol Ther (Seoul)* 2020;28:370-9.
- Alberti C. Apoptosis induction by quinazoline-derived alpha1-blockers in prostate cancer cells: biomolecular implications and clinical relevance. *Eur Rev Med Pharmacol Sci* 2007;11:59-64.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. *CA Cancer J Clin* 2018;68:7-30.
- Janz TA, Neskey DM, Nguyen SA, et al. Is the incidence

- of anaplastic thyroid cancer increasing: A population based epidemiology study. *World J Otorhinolaryngol Head Neck Surg* 2019;5:34-40.
22. Mohan DR, Lerario AM, Finco I, et al. New strategies for applying targeted therapies to adrenocortical carcinoma. *Curr Opin Endocr Metab Res* 2019;8:72-9.
 23. Hu S, Liao Y, Chen L. Identification of Key Pathways and Genes in Anaplastic Thyroid Carcinoma via Integrated Bioinformatics Analysis. *Med Sci Monit* 2018;24:6438-48.
 24. Zhu LY, Zhu YR, Dai DJ, et al. Epigenetic regulation of alternative splicing. *Am J Cancer Res* 2018;8:2346-58.
 25. Wan Y, Zhang X, Leng H, et al. Identifying hub genes of papillary thyroid carcinoma in the TCGA and GEO database using bioinformatics analysis. *PeerJ* 2020;8:e9120.
 26. Ding C, Wei R, Rodríguez RA, et al. LncRNA PCAT-1 plays an oncogenic role in epithelial ovarian cancer by modulating cyclinD1/CDK4 expression. *Int J Clin Exp Pathol* 2019;12:2148-56.
 27. Tan SH, Barker N. Wnt Signaling in Adult Epithelial Stem Cells and Cancer. *Prog Mol Biol Transl Sci* 2018;153:21-79.
 28. Benard O, Qian X, Liang H, et al. p21CIP1 Promotes Mammary Cancer-Initiating Cells via Activation of Wnt/TCF1/CyclinD1 Signaling. *Mol Cancer Res* 2019;17:1571-81.
 29. Kai J, Wang S. Recent progress on elucidating the molecular mechanism of plasmid-mediated colistin resistance and drug design. *Int Microbiol* 2020;23:355-66.
 30. Sun GC, Liang WZ, Jan CR. Mechanisms underlying the effect of an oral antihyperglycaemic agent glyburide on calcium ion (Ca²⁺) movement and its related cytotoxicity in prostate cancer cells. *Clin Exp Pharmacol Physiol* 2020;47:111-8.
 31. Gao X, Abdelkarim H, Albee LJ, et al. Partial agonist activity of α 1-adrenergic receptor antagonists for chemokine (C-X-C motif) receptor 4 and atypical chemokine receptor 3. *PLoS One* 2018;13:e0204041.
 32. Zhang Y, Berger SA. Increased calcium influx and ribosomal content correlate with resistance to endoplasmic reticulum stress-induced cell death in mutant leukemia cell lines. *J Biol Chem* 2004;279:6507-16.
 33. Sebastian J, Rathinasamy K. Sertaconazole induced toxicity in HeLa cells through mitotic arrest and inhibition of microtubule assembly. *Naunyn Schmiedebergs Arch Pharmacol* 2021;394:1231-49.
 34. Dong C, Chen Y, Ma J, et al. Econazole nitrate reversed the resistance of breast cancer cells to Adriamycin through inhibiting the PI3K/AKT signaling pathway. *Am J Cancer Res* 2020;10:263-74.
- (English Language Editor: A. Kassem)

Cite this article as: Du L, Zhao Q, Li J, Wang M, Qiao H. Expression of colorectal neoplasia differentially expressed in anaplastic thyroid carcinoma and its effect on cancer cell proliferation. *Ann Transl Med* 2022;10(8):473. doi: 10.21037/atm-22-945

Table S1 Clinical characteristics of thyroid cancer patients from TCGA

Variables		Patients (N=502)	
		n	%
Age	years (mean, range)	47.34 (15.00-89.00)	/
Overall survival times	days (mean, range)	1209.7 (0-5423.0)	/
Overall survival status	Alive	486	96.81
	Dead	16	3.19
Gender	Female	367	73.11
	Male	135	26.89
Race	White	332	66.13
	Others	79	15.74
	Unknown	91	18.13
Thyroid disorder history	Lymphocytic thyroiditis	47	9.36
	Nodular hyperplasia	68	13.55
	Lymphocytic thyroiditis and nodular hyperplasia	24	4.78
	Normal	280	55.78
	Others	25	4.98
	Unknown	58	11.55
PTC subtype	Classical	356	70.92
	Follicular	101	20.12
	Tall Cell	36	7.17
	Others	9	1.79
Location	Bilateral	86	17.13
	Isthmus	22	4.38
	Left lobe	175	34.86
	Right lobe	213	42.43
	Unknown	6	1.20
Residual tumor	R0	384	76.49
	R1	52	10.36
	R2	4	0.80
	RX	30	5.98
	Unknown	32	6.37
Tumor stage	Stage I	281	55.98
	Stage II	52	10.36
	Stage III	112	22.31
	Stage IV	55	10.96
	Unknown	2	0.40
T stage	T1	143	28.49
	T2	164	32.67
	T3	170	33.86
	T4	23	4.58
	TX	2	0.40
N stage	N0	229	45.62
	N1	223	44.42
	NX	50	9.96
M stage	M0	282	56.18
	M1	9	1.79
	MX	210	41.83
	Unknown	1	0.20

TCGA, The Cancer Genome Atlas.

Table S2 The correlation between CRNDE and genes in the WNT signaling pathway

LncRNA	mRNA	P value	Cor	Slope
CRNDE	FZD2	1.17E-11	0.30	0.23
CRNDE	FOSL1	1.29E-09	0.27	0.35
CRNDE	TCF7L1	1.32E-08	0.25	0.28
CRNDE	NFATC1	1.71E-08	0.25	0.16
CRNDE	CSNK1E	2.93E-07	0.23	0.09
CRNDE	WNT2B	6.76E-07	0.22	0.09
CRNDE	WNT5B	2.07E-06	0.21	0.18
CRNDE	VANGL1	2.44E-06	0.21	0.12
CRNDE	PPP2R5B	3.36E-06	0.21	0.08
CRNDE	FZD10	1.27E-05	0.19	0.12
CRNDE	PRICKLE2	1.28E-05	0.19	0.12
CRNDE	RAC3	2.15E-05	0.19	0.14
CRNDE	SOX17	7.09E-05	0.18	0.13
CRNDE	LEF1	1.12E-04	0.17	0.16
CRNDE	PLCB3	1.22E-04	0.17	0.05
CRNDE	PPP2R1B	1.22E-04	0.17	0.06
CRNDE	ROCK2	1.29E-04	0.17	0.08
CRNDE	PLCB1	1.98E-04	0.17	0.09
CRNDE	FZD7	3.19E-04	0.16	0.12
CRNDE	WIF1	3.23E-04	0.16	0.16
CRNDE	SMAD3	5.49E-04	0.15	0.08
CRNDE	WNT9A	1.28E-03	0.14	0.09
CRNDE	RUVBL1	1.38E-03	0.14	0.03
CRNDE	WNT7B	1.98E-03	0.14	0.11
CRNDE	TP53	1.99E-03	0.14	0.05
CRNDE	PRICKLE1	2.27E-03	0.14	0.14
CRNDE	RBX1	2.95E-03	0.13	0.05
CRNDE	NKD1	3.22E-03	0.13	0.06
CRNDE	WNT11	4.26E-03	0.13	0.14
CRNDE	TCF7L2	4.28E-03	0.13	0.06
CRNDE	RAC1	4.98E-03	0.13	0.02
CRNDE	CCND1	5.17E-03	0.12	0.09
CRNDE	SFRP5	5.75E-03	0.12	0.06
CRNDE	SFRP4	6.17E-03	0.12	0.25
CRNDE	JUN	6.79E-03	0.12	0.13
CRNDE	PLCB4	6.97E-03	0.12	0.13
CRNDE	WNT4	9.78E-03	0.12	0.16
CRNDE	PORCN	1.15E-02	0.11	0.07
CRNDE	WNT3A	1.25E-02	0.11	0.06
CRNDE	DKK2	1.31E-02	0.11	0.09
CRNDE	WNT6	1.51E-02	0.11	0.05
CRNDE	FRAT1	1.60E-02	0.11	0.04
CRNDE	SFRP2	1.91E-02	0.10	0.30
CRNDE	FZD6	2.15E-02	0.10	0.07
CRNDE	FZD8	2.26E-02	0.10	0.08
CRNDE	WNT16	3.00E-02	0.10	0.04
CRNDE	FZD4	3.86E-02	0.09	0.06

CRNDE, colorectal neoplasia differentially expressed; LncRNA, long-noncoding RNA; WNT, wnt signaling pathway.